Acacia Research reported second-quarter 2026 revenue of $114.6 million, more than double the prior-year quarter's $51.2 million, but the headline is a single one-time paid-up license agreement that drove essentially the entire increase. The $60.6 million Q2 paid-up license revenue was a one-shot, while the more meaningful six-month comparison shows total revenue actually down 4% year over year, the company slipped into a small GAAP net loss of $0.16 per share, and a $30.9 million impairment of the legacy MalinJ1 life-sciences investment, written down to zero in the quarter, dragged reported results below operating reality.
The $4.59 share price on August 12, 2026 sits below book value of $5.41 per share, but the discount is misleading because reported book value is depressed by the same $30.9 million non-cash impairment that hit the quarter; pre-impairment book value is closer to $5.72. With $307.6 million of cash and equivalents, $90.4 million of subsidiary-level debt at Benchmark and Deflecto, and an operating-business-only enterprise value of roughly $230 million, the equity at $447.9 million market capitalization is asking the market to value the four operating segments and a $326.8 million liquid securities portfolio at a discount to a clean sum-of-the-parts.
The single most important data point for the next twelve months is whether Acacia replaces the Q2 paid-up spike with recurring revenue from a new patent portfolio, because the company has not acquired a new patent portfolio since 2025 and the Wi-Fi 6 portfolio that drove $60.6 million in paid-up revenue this quarter is in the back half of its economic life.